Noncholestatic acute hepatocellular injury following candesartan administration.
Jan Antonio Lammel-LindemannEduardo Flores-VillalbaAlexandro Jose MartagónEduardo DeObeso-GonzalezFrancisco Puente-GallegosPublished in: British journal of clinical pharmacology (2017)
Arterial hypertension is a highly manageable disorder due to a variety of drugs available for its treatment. Since the late 1990s, angiotensin II receptor blockers have been widely prescribed, achieving appropriate control in patients' blood pressure. Few cases of serious adverse effects have been reported to date. Here, we present a case of acute hepatocellular injury secondary to candesartan administration. Further studies should be performed in patients who present with this adverse effect, in order to prevent more serious outcomes.
Keyphrases
- angiotensin ii
- angiotensin converting enzyme
- liver failure
- blood pressure
- arterial hypertension
- end stage renal disease
- respiratory failure
- drug induced
- newly diagnosed
- vascular smooth muscle cells
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- aortic dissection
- emergency department
- type diabetes
- heart rate
- patient reported outcomes
- metabolic syndrome
- insulin resistance
- mechanical ventilation
- acute respiratory distress syndrome
- glycemic control